For a T-cell dependent bispecific antibody targeting HER2 and CD3 it has been shown that introducing an additional binding moiety for HER2 led to increased tumor cell selectivity and highly potent targeting of HER2-positive target cells, while sparing cells that express low amounts of HER241. Here, ERBB2 is linked to neoplasm.